Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.
Cell Host Microbe. 2021 04 14; 29(4):522-528.e2.CH

Abstract

Toward eradicating the COVID-19 pandemic, vaccines that induce high humoral and cellular immune responses are essential. However, SARS-CoV-2 variants have begun to emerge and raise concerns, as they may potentially compromise vaccine efficiency. Here, we monitored neutralization potency of convalescent or Pfizer-BTN162b2 post-vaccination sera against pseudoviruses displaying spike proteins derived from wild-type SARS-CoV-2, or its UK-B.1.1.7 and SA-B.1.351 variants. Compared to convalescent sera, vaccination induces high titers of neutralizing antibodies, which exhibit efficient neutralization potential against pseudovirus carrying wild-type SARS-CoV-2. However, while wild-type and UK-N501Y pseudoviruses were similarly neutralized, those displaying SA-N501Y/K417N/E484K spike mutations moderately resist neutralization. Contribution of single or combined spike mutations to neutralization and infectivity were monitored, highlighting mechanisms by which viral infectivity and neutralization resistance are enhanced by N501Y or E484K/K417N mutations. Our study validates the importance of the Pfizer vaccine but raises concerns regarding its efficacy against specific SARS-CoV-2 circulating variants.

Authors+Show Affiliations

The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. Electronic address: kuzmina@post.bgu.ac.il.Soroka Medical Center, Beer Sheva, Israel.Soroka Medical Center, Beer Sheva, Israel.Soroka Medical Center, Beer Sheva, Israel.Soroka Medical Center, Beer Sheva, Israel.Soroka Medical Center, Beer Sheva, Israel.The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Soroka Medical Center, Beer Sheva, Israel.Soroka Medical Center, Beer Sheva, Israel.The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. Electronic address: rantaube@bgu.ac.il.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33789085

Citation

Kuzmina, Alona, et al. "SARS-CoV-2 Spike Variants Exhibit Differential Infectivity and Neutralization Resistance to Convalescent or Post-vaccination Sera." Cell Host & Microbe, vol. 29, no. 4, 2021, pp. 522-528.e2.
Kuzmina A, Khalaila Y, Voloshin O, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021;29(4):522-528.e2.
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Boehm-Cohen, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R. (2021). SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host & Microbe, 29(4), 522-e2. https://doi.org/10.1016/j.chom.2021.03.008
Kuzmina A, et al. SARS-CoV-2 Spike Variants Exhibit Differential Infectivity and Neutralization Resistance to Convalescent or Post-vaccination Sera. Cell Host Microbe. 2021 04 14;29(4):522-528.e2. PubMed PMID: 33789085.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. AU - Kuzmina,Alona, AU - Khalaila,Yara, AU - Voloshin,Olga, AU - Keren-Naus,Ayelet, AU - Boehm-Cohen,Liora, AU - Raviv,Yael, AU - Shemer-Avni,Yonat, AU - Rosenberg,Elli, AU - Taube,Ran, Y1 - 2021/03/20/ PY - 2021/02/17/received PY - 2021/03/10/revised PY - 2021/03/16/accepted PY - 2021/4/1/pubmed PY - 2021/4/29/medline PY - 2021/3/31/entrez KW - COVID-19 KW - Pfizer-BTN162b2 vaccine KW - SARS-CoV-2 KW - Spike KW - UK and SA variants KW - United Kingdom and South African variants KW - neutralization antibodies SP - 522 EP - 528.e2 JF - Cell host & microbe JO - Cell Host Microbe VL - 29 IS - 4 N2 - Toward eradicating the COVID-19 pandemic, vaccines that induce high humoral and cellular immune responses are essential. However, SARS-CoV-2 variants have begun to emerge and raise concerns, as they may potentially compromise vaccine efficiency. Here, we monitored neutralization potency of convalescent or Pfizer-BTN162b2 post-vaccination sera against pseudoviruses displaying spike proteins derived from wild-type SARS-CoV-2, or its UK-B.1.1.7 and SA-B.1.351 variants. Compared to convalescent sera, vaccination induces high titers of neutralizing antibodies, which exhibit efficient neutralization potential against pseudovirus carrying wild-type SARS-CoV-2. However, while wild-type and UK-N501Y pseudoviruses were similarly neutralized, those displaying SA-N501Y/K417N/E484K spike mutations moderately resist neutralization. Contribution of single or combined spike mutations to neutralization and infectivity were monitored, highlighting mechanisms by which viral infectivity and neutralization resistance are enhanced by N501Y or E484K/K417N mutations. Our study validates the importance of the Pfizer vaccine but raises concerns regarding its efficacy against specific SARS-CoV-2 circulating variants. SN - 1934-6069 UR - https://www.unboundmedicine.com/medline/citation/33789085/SARS_CoV_2_spike_variants_exhibit_differential_infectivity_and_neutralization_resistance_to_convalescent_or_post_vaccination_sera_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1931-3128(21)00136-0 DB - PRIME DP - Unbound Medicine ER -